234 related articles for article (PubMed ID: 15331055)
1. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
[TBL] [Abstract][Full Text] [Related]
2. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
3. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
[TBL] [Abstract][Full Text] [Related]
4. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
Hu X; Stebbins CE
Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
[TBL] [Abstract][Full Text] [Related]
7. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional quantitative structure-activity relationship study for phenylsulfonyl carboxylates using CoMFA and CoMSIA.
Liu X; Yang Z; Wang L
Chemosphere; 2003 Dec; 53(8):945-52. PubMed ID: 14505717
[TBL] [Abstract][Full Text] [Related]
9. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
10. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
Puntambekar DS; Giridhar R; Yadav MR
Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory mode of indole-2-carboxamide derivatives against HLGPa: molecular docking and 3D-QSAR analyses.
Liu G; Zhang Z; Luo X; Shen J; Liu H; Shen X; Chen K; Jiang H
Bioorg Med Chem; 2004 Aug; 12(15):4147-57. PubMed ID: 15246091
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
[TBL] [Abstract][Full Text] [Related]
14. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
Kamath S; Buolamwini JK
J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases.
Thaimattam R; Daga PR; Banerjee R; Iqbal J
Bioorg Med Chem; 2005 Aug; 13(15):4704-12. PubMed ID: 15914012
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
18. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors.
Castilho MS; Postigo MP; de Paula CB; Montanari CA; Oliva G; Andricopulo AD
Bioorg Med Chem; 2006 Jan; 14(2):516-27. PubMed ID: 16203153
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter.
Geldenhuys WJ; Lockman PR; Nguyen TH; Van der Schyf CJ; Crooks PA; Dwoskin LP; Allen DD
Bioorg Med Chem; 2005 Jul; 13(13):4253-61. PubMed ID: 15878282
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Bhongade BA; Gadad AK
Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
